Advanced and Targeted Drug Delivery Market Segmentation, Analysis & Forecast to 2021

Published: 2016-APR-04  
Pages: 382  
Format: PDF  
Price: 3800 USD (Single User License)

**Description**  
Advanced and Targeted Drug Delivery Market Segmentation, Analysis & Forecast to 2021: Nanoparticles, Polymers, Liposomes, Micelles, Nanoemulsions, Dendrimers, Monoclonal Antibodies by Geography, Therapeutic Area and Stakeholder Environment

This newly published report is a global industry analysis on the advanced and targeted drug delivery market that KellySciPub forecasts to grow at a 10.4% CAGR to $319 billion by 2021 from $168 billion today. Supported by over 300 tables and figures, this 382 page report is an extensive industry analysis specifically written for C-Suite, VP and Higher executives within the Pharma and Biotech space.

The advanced and targeted drug delivery market is segmented and analysed through to 2021 with corresponding CAGR breakdown by:
- **Technology**: Nanoparticles, Polymers (micelles, dendrimers etc), Monoclonal antibodies, Gold nanoparticles-based drug delivery and imaging, Drug eluting stents
- **Geography**: Global, USA, Europe, RoW
- **Therapeutic Area**: Pulmonary, Ocular drug delivery, Ocular nano-based drug delivery implants, Drug Eluting Stents,
- **Sub-Market Analysis**: (details below)

The monoclonal antibody market is further broken down and presented as the top selling mAbs by company, class and revenue through to 2021 with corresponding CAGR values. Specific figures are given in relation to Humira, Remicade, Avastin, Rituxan, Soliris, Herceptin, Kadcyla, Perjeta, Lucentis, Xgeva/Prolia, Stelara and Tysarbi.

The global market for nano-based targeted drug delivery is presented by the following sub-markets liposomes, polymers (micelles, dendrimers etc) and gold nano-particles through to 2021 with corresponding CAGR figures.

The global pulmonary drug delivery market is analysed and presented as metered dose inhalers (MDIs), dry powder inhalers (DPIs) and nebulizers through 2021 with corresponding CAGR data. This market is also divided into the following geographical regions USA, Europe, RoW, Global through 2021 with corresponding CAGR analysis.

Our PhD analysts identify breakthrough R&D papers and patents and delve into disruptive technical platforms that is revolutionising drug delivery systems. Business, financial and market analysis is performed on all data collated to yield robust figures and forecast through 2021 with CAGR values. Together, our scientific and business team provides you with their in depth knowledge, experience and perspective on the targeted drug delivery landscape.

Stake holder analysis of key players including innovators, developers and commercial partners is performed and an in depth chapter of 170 companies involved is presented.

The analysis includes details of how is breakthrough technology adoption is changing the drug delivery landscape and also how emerging products like hydrogels, PEGylated phospholipid nanocarriers and cyclodextrins are disrupting conventional markets.

Key Questions Answered in this Report:

http://www.biomarketgroup.com
BioMarket Group - A Global Online Aggregator of Life Science Market Research

• What are the maximum drug release times reported for various nano-based drug carriers?
• What regulatory agencies are approving specific nanomedicines?
• How many liposome-based drugs are available in the market?
• How many stealth liposomes have been granted market approval?
• How many PEGylated liposomes are used for targeted drug delivery?
• Who are the leading players in liposome-based drug formulation?
• What are stimuli-responsive polymers?
• Who are the market leaders in polymer-based drugs?
• What dendrimer-based drugs are the commercially available for targeted delivery?
• What are the applications of inorganic nanoparticles in targeted drug delivery?
• Which companies are focusing on inorganic nanoparticles for targeted drug delivery?
• What are the applications of magnetic nanoparticles in drug delivery, diagnostic and imaging?
• What is the global market value of nanomedicines?
• What is the global market for nanomedicines by therapeutic areas?
• What is the global market for monoclonal antibodies by geography?
• What are the best-selling mAbs?
• What is the global market for major targeted delivery systems?

Table of Contents

1.0 Introduction 26

1.1 Executive Summary 26

1.2 About this Report 29

1.3 Key Questions Answered in this Report 29

2.0 Targeted Drug Delivery: An Overview 31

2.1 The Need for Targeted Delivery 31

2.2 Advantages and Disadvantages of Targeted Drug Delivery 32

2.3 Types of Drug Targeting 32

2.3.1 Active Targeting 33

2.3.2 Passive Targeting 34

2.3.2.1 Passively Targeted Therapeutic Preparations 35

2.3.2.2 Polymeric Nanoparticles (NPs) Developed for Passive Delivery of Drugs 35

2.4 Ideal Characteristics of Targeted Drug Delivery Carriers 36

2.5 Drug Carriers used in Targeting Systems 37

3.0 Targeted Drug Delivery and Nanomedicines: An Overview 38

3.1 Ideal Characteristics of Nanoparticles suited for Targeted Delivery 38

3.2 Size of Therapeutic Nanoconstructs 38

3.3 Examples of Nanomedicines Approved by One or More Regulatory Bodies 39

3.3.1 Brief Description of Approved Nanomedicines 40

3.3.1.1 Doxil 40

3.3.1.2 Myocet 40

3.3.1.3 DaunoXome 41

3.3.1.4 ThermoDox 41

3.3.1.5 Abraxane 41

http://www.biomarketgroup.com
3.3.1.6 Rexin-G 42
3.3.1.7 Oncaspar 42
3.3.1.8 Resovist 42
3.3.1.9 Feridex 42
3.3.1.10 Marquibo 42
3.3.1.11 Brentuximab Vedotin (Adectris) 43
3.3.1.12 Trastuzumab Emtansine (Kadcyla) 43
3.3.2 Therapeutic Nanomedicines in Clinical Trials 43
3.4 Targeting Approaches of Nanomedicines 45
3.4.1 Targets of Nanomedicines in the Body 45
3.4.2 Targeting Ligands 46
3.5 Mechanism of Internalization of Nanomedicine 47
3.6 Future Direction of Nanomedicines 47
3.7 Examples of Nanomedicine Applications 48
3.8 Rationale for Nanomedicine Approach 49
3.9 Commercially Available Oral Nanotherapeutics 49
3.10 Commercially Available Nanotherapeutics for Parenteral Administration 50
3.11 Examples of FDA-Approved Nanomedicines for Intravenous Route of Administration 52
3.12 Examples of FDA-Approved Nanomedicines for Pulmonary Route of Administration 52
3.13 Examples of FDA-Approved Nanomedicines for Subcutaneous, Intramuscular, Transdermal and Ocular Route of Administration 53
3.14 Examples of Nano-Based Medical Devices and Diagnostics 54
3.15 Various Types of Nanocarriers Exploited in Formulating Nanomedicines 55
3.15.1 Types of Nanoparticles 56
3.16 Use of Nanoparticles in Different Fields of Medicine 56
3.16.1 Nanosystems for Cancer Treatment 57
3.16.2 Use of Nanosystems in Tissue Engineering 58
3.16.3 Use of Nanoparticles (NPs) in Stem Cell Therapy 59
3.16.4 Use of Nanoparticles in Contrast Agents 59
3.17 Segmentation of Targeted Drug Delivery Nanosystems 60
4.0 Lipid-Based Targeted Drug Delivery Nanosystems 61
4.1 Advantages and Disadvantages of Liposomes as Targeted Drug Delivery Systems 61
4.2 Classification of Liposomes on the Basis of Size and Composition 62
4.2.1 Classification of Liposomes on the Basis of Method of Preparation 63
4.3 Size of Liposomes 63
4.4 New Generation of Liposomes and their Features 63
6.6 Multifunctional Polymeric Micelles 93

6.6.1 Examples of Multifunctional Drug-Loaded Micelle 93

6.6.2 Multifunctional Micelles for the Delivery of siRNA 94

6.7 Drug-Loaded Polymeric Micelle-Based Products in Development 95

7.0 Dendrimer-Based Targeted Drug Delivery 97

7.1 Three-Dimensional Structure of Dendrimers 97

7.2 Dendrons as Multifunctional Nanoplatforms 97

7.3 Commercially Available and Late-Stage Dendrimers 98

7.4 Therapeutic Moieties studied using Dendrimer Platform 99

7.5 Thermosensitive Dendrimers 100

8.0 Inorganic Nanoparticles for Targeted Drug Delivery 102

8.1 Companies Focusing on Inorganic Nanoparticles 102

8.2 Carbon-Based Nanoparticles for Drug Delivery 102

8.2.1 Carbon Nanotubes (CNTs) 103

8.2.1.1 Structure of Carbon Nanotubes 104

8.2.1.2 Artificial Implants from Carbon Nanotubes (CNTs) 104

8.2.1.3 Detection of Cancer Biomarker by Carbon Nanotubes 105

8.2.1.4 Drug and Gene Delivery by Carbon Nanotubes 106

8.3 Fullerences 106

8.3.1 Structure of Fullerene 106

8.3.2 Biomedical Applications of Fullerences 107

8.4 Graphene Oxide (GO) as Nanocarriers 108

8.4.1 GO for Drug Delivery 109

8.5 Gold-Based Nanoparticles (AuNPs) 109

8.5.1 Shapes of Gold Nanoparticles 110

8.5.2 Imaging Applications of Gold Nanoparticles 110

8.5.3 Drug Delivery Applications of Gold Nanoparticles 111

8.5.4 Diagnostic Applications of Gold Nanoparticles 111

8.6 Silica Nanoparticles for Drug Delivery 112

8.6.1 Types of Silica Nanoparticles 112

8.6.2 The Process of Synthesis of SNs 113

8.6.3 Drugs Delivered through Silica Nanoparticles 114

8.7 Magnetic Particles for Drug Delivery 115

8.7.1 Companies Focusing on Magnetic Particles 115

8.7.2 Typical Design of a Magnetic Nanoparticle 115

8.7.3 Use of Magnetic Nanoparticles 116
8.7.4 Diagnostic Use 116
8.7.5 Coating Materials for Magnetic Nanoparticles 117
8.7.6 Organic Linkers in Magnetic Nanoparticles 117
8.7.7 Targeted Magnetic Nanoparticles (MNPs) as Cancer Theranostics 118
8.7.8 Targeting Magnetic Nanoparticles to Tumors (Passive and Active) 118
8.7.9 Magnetic Nanoparticles as Diagnostics 119
8.7.10 Magnetic Nanoparticles as Multimodal Imaging Agents 120
8.7.11 FDA/EMEA Approved Magnetic Nanoparticle-Based Contrast Agents 120
9.0 Cell-Based Systems for Targeted Delivery 122
9.1 Companies Focusing on Cell-Based Carriers 122
9.2 Role of Dendritic Cells (DCs) in Drug Delivery 122
9.3 Engineered RBCs for Drug Delivery 124
9.3.1 Therapeutic Sites and Targets Accessible for RBC-Delivered Drugs 124
9.3.2 Examples of Therapeutic Enzymes Encapsulated in Carrier RBCs 125
9.4 Stem Cells for Drug Delivery 125
9.5 Bacterial Ghosts for Drug Delivery 126
10.0 Nucleic Acid/Peptide as Drug Carriers 127
10.1 Companies Focusing on Aptamers/Nucleic Acids/Peptides 127
10.2 Peptide Conjugates for Drug Delivery 127
10.2.1 Peptides as Radionuclide Carriers 128
10.2.3 Peptide Hormones 129
10.2.4 Peptide Vaccines 129
10.2.5 Peptide as Cytotoxic Drug Carrier 130
10.2.6 Cell-Penetrating Peptides 131
10.2.7 Peptides Applied in Cancer Diagnostics 131
10.2.8 Peptides Applied in Treating Cancer 132
10.2.9 Peptide-Based Vaccines in Clinical Development 133
10.3 DNA/RNA Aptamers 133
10.3.1 Clinical Use of Aptamers 134
10.4 DNA Origami (DNA Nanorobots) 135
11.0 Targeted Therapies by Indication: An Overview 136
11.1 Targeted Cancer Therapies 136
11.1.1 Identification of Targets in Cancer Therapy 137
11.1.2 Categories and Examples of Tumor Antigens 137
11.1.3 Development of Targeted Therapies for Cancer 139

http://www.biomarketgroup.com
BioMarket Group - A Global Online Aggregator of Life Science Market Research

11.1.4 Targeted Cancer Therapies in Late Stage Development 140

11.1.5 Companies Focusing on Oncology Applications of Targeted Drug Delivery 140

11.2 Monoclonal Antibodies (mAbs) and Targeted Drug Delivery 141

11.2.1 Monoclonal Antibodies (mAbs) 141

11.2.1.1 Naked mAbs 142

11.2.1.2 Examples of Naked mAbs and their Functions 142

11.2.1.3 Conjugated mAbs 143

11.2.1.4 Bispecific mAbs 145

11.2.2 U.S./E.U.-Approved mAbs 146

11.2.3 mAbs by Indication Area 147

11.2.4 mAb Biosimilars in Late Stage Development 147

11.2.5 Biosimilar mAbs in Development 148

11.3 Ocular Applications of Targeted Drug Delivery 148

11.3.1 Ocular Applications of Dendrimer Systems 149

11.3.2 Ocular Applications of Liposomes 150

11.3.3 Micelles in Ocular Drug Delivery 151

11.3.3.1 Micelle Systems Investigated for Ocular Drug Delivery 151

11.3.4 Viral and Non-Viral Vectors for Ocular Gene Delivery 152

11.4 Targeted Drug Delivery for Central Nervous System (CNS) Disorders 153

11.4.1 Blood Brain Barrier (BBB) 153

11.4.2 Drug Delivery Approaches and Drug Molecules for Brain 154

11.4.3 Examples of Nanoparticles (NPs) used for Delivery of Drugs across BBB 155

11.4.4 Examples of Clinically-Approved NPs Therapeutics for CNS Disorders 155

11.4.5 Dendrimers for CNS Drug Delivery 156

11.5 Infectious Disease Applications for Targeted Drug Delivery 157

11.5.1 Liposomes for Antimicrobial Drug Delivery 157

11.5.2 Polymeric Nanoparticles for Antimicrobial Drug Delivery 158

11.5.3 Solid Lipid Nanoparticles (SLNs) for Antimicrobial Drug Delivery 159

11.5.4 Dendrimers for Antimicrobial Drug Delivery 160

11.6 Cardiovascular Applications for Targeted Drug Delivery 160

11.6.1 Nanoparticles for Advanced Diagnostics and Therapy of Cardiovascular Diseases 161

11.6.2 Therapeutic and Theranostic Nanoparticles for CVD 161

11.6.3 In vivo Nanosensors for CVD 162

11.7 Targeted Drug Delivery for Pulmonary Diseases 163

11.7.1 Drugs for Inhalation 163

11.7.2 Polymers for Colloidal Pulmonary Drug Delivery Systems 164
11.7.3 Nebulizers with Novel Technologies for Pulmonary Drug Delivery 166
11.7.4 Novel Dry Powder Inhalers (DPis) 166
11.7.5 Types of Nanoparticles used to Encapsulate API Molecules 167
11.8 Cosmeceutical Applications of Nano-Based Drugs for Targeted Delivery 168
12.0 Other Targeted Drug Delivery Technologies 170
12.1 Ocular Implants 170
12.1.1 Ocular Implants under Clinical Development 170
12.1.2 FDA-Approved Ocular Drug Delivery Implants 171
12.1.3 Sustained Trans-Scleral Ocular Drug Delivery 172
12.2 Drug Eluting Stents (DES) and Targeted Drug Delivery 173
12.2.1 Polymers for Stent Coatings 173
12.3 Microchips: The Novel Implantable Drug Delivery Technology 174
13.0 Market Analysis to 2021 176
13.1 Applications of Nanoparticles in Healthcare 176
13.2 Types of Nanomedicine Companies 177
13.3 Global Market for Nanomedicines to 2021 177
13.3.1 Nanomedicines Market by Major Therapeutic Area 178
13.4 Global Market for Targeted Drug Delivery to 2021 180
13.4.1 Global Market for mAbs to 2021 182
13.4.1.1 Best-Selling mAbs 2014-2021 183
13.4.1.2 Global Market for Humira, Remicade and Avastin 183
13.4.1.3 Global Market for Rituxan, Soliris and Herceptin 184
13.4.1.4 Global Market for Kadcyla, Perjeta and Lucentis 185
13.4.1.5 Global Market for Xgeva/Prolia, Stelara and Tysarbi 186
13.5 Global Market for Nanoparticle-Based Targeted Drug Delivery Systems to 2021 187
13.6 Ocular Drug Delivery Market to 2021 188
13.6.1 Novel Ocular Drug Delivery Systems 189
13.6.1.2 Ocular Drug Delivery Implants 190
13.7 Global Market for Implanted Drug Eluting Stents to 2021 192
13.8 Pulmonary Drug Delivery to 2021 193
13.9 What does the Future hold for the Targeted Drug Delivery Market? 195
13.10 Impact of New Technology Systems on the Current Targeted Delivery Market 196
13.11 Future Directions in Drug Delivery 197
13.12 Disruptive Technologies within the Existing Targeted Delivery Market 197
13.12.1 Emergence of Hydrogels in Oral Drug Delivery 197
13.12.2 Emergence of PEGylated Phospholipid Nanocarriers for Respiratory Diseases 198

13.12.3 Emergence of Cyclodextrins 199

13.12.3.1 Cyclodextrins in Oral Drug Delivery 199

13.12.3.2 Cyclodextrins in Rectal Drug Delivery 200

13.12.3.3 Cyclodextrin in Nasal Drug Delivery 200

13.12.3.4 Cyclodextrins in Transdermal Drug Delivery 200

13.12.3.5 Cyclodextrins in Ocular Drug Delivery 201

13.12.3.6 Cyclodextrins in Controlled Drug Delivery 201

14.0 Selected Company Profiles 203

14.1 3M Company 203

14.1.1 3M Drug Delivery Systems 203

14.2 Abbott Laboratories 203

14.2.1 Gengraf 203

14.2.2 Kaletra 204

14.2.3 Norvir 204

14.3 Ablynx NV 204

14.3.1 Nanobody Technology 204

14.3.2 Clinical Programs 205

14.3.3 Ablynx’s Partnership with Boehringer Ingelheim 205

14.3.4 Ablynx’s Partnership with Eddingpharm 206

14.3.5 Ablynx’s Partnership with Genzyme 206

14.3.6 Ablynx’s Partnership with Merck & Co. 206

14.3.7 Ablynx’s Partnership with Merck KGaA 206

14.3.8 Ablynx’s Partnership with Novartis 206

14.3.9 Ablynx’s Partnership with Taisho Pharmaceutical 207

14.4 Aciont Inc. 207

14.4.1 Visulex Technology 207

14.5 Acrux 208

14.5.1 Patchless Patch 208

14.5.2 Axiron 208

14.5.3 Evamist & Lenzetto 208

14.6 Agilis Biotherapeutics LLC 209

14.6.1 Agilis’ Engineered DNA Therapeutics 209

14.6.2 Agilis’ DNA Therapeutic Programs 209

14.6.2.1 DNA Therapeutics for Friedreich’s Ataxia 209

14.6.2.2 DNA Therapeutics for Angelman Syndrome (AS) 209
14.7 Aileron Therapeutics Inc. 210
14.7.1 P53 Pathway Re-Activator 210
14.8 Alchemia Oncology Pty Ltd. 211
14.8.1 HA-Irinotecan 211
14.8.2 HA-Doxorubicin (Hyaluronic acid + Doxorubicin) 211
14.8.3 HA-5-Fluorouracil (Hyaluronic acid + 5-Fluorouracil) 211
14.8.4 Monoclonal Antibodies 212
14.9 Alkermes Pharma Ireland Ltd. 212
14.9.1 Aristada 212
14.9.2 Vivitrol 212
14.9.3 U.S. Products using Alkermes' Technologies 213
14.9.3.1 Bydureon 213
14.9.3.2 Ampyra 213
14.9.3.3 Risperdal Consta 213
14.9.3.4 Invega Trinza 213

Ordering

Order by Fax - using the form below

Order by Post - print the order form below and send to:
BioMarket Group
Björnnäsvägen 21
11419 STOCKHOLM
SWEDEN
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to +46-8-56849191. If you have any questions please visit http://www.biomarketgroup.com/market-research-report/contacts/

Order Information
Please verify that the product information is correct:

Product Name: Advanced and Targeted Drug Delivery Market Segmentation, Analysis & Forecast to 2021
Format: PDF
Price: 3800 USD (Single User License)

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: ____________________________
Name: ____________________________
Email Address:* ____________________
Job Title: __________________________
Organization: ______________________
EU companies must supply: VAT / BTW / MOMS MWST / IVA / FPA number: __________________________
Address: ____________________________
Zip Code: ____________________________
City: ________________________________
State: _______________________________
Country: ____________________________
Phone Number: ________________________
Fax Number: _________________________

Payment Information
Please indicate the payment method you would like to use by selecting the appropriate box.

[ ] Pay by credit card:
[ ] American Express
[ ] Master Card
[ ] Visa

Cardholder Name: ____________________________
Expiry Date (MM/YY): ____________________________
Card Number: ____________________________
CVV Number: ____________________________

[ ] Pay by check:
Please post the check, accompanied by this form, to:
BioMarket Group
Björnnäsvägen 21
11419 STOCKHOLM
SWEDEN

[ ] Pay by wire transfer: Please transfer funds to:
Account number: 43521169
Swift code: HANDSESS
IBAN number: SE74 6000 0000 0000 4352 1169
Bank Address: Handelsbanken, Stockholm, Sweden

If you have a Marketing Code please enter it below:
Marketing Code: ____________________________

Please supply purchase order number if needed:

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, Gmail)

Please note that by ordering from BioMarket Group you are agreeing to our Terms and Conditions at http://www.biomarketgroup.com
Please fax this form to: +46-8-56849191